An amince da alamar Ameile ta huɗu don tallatawa, wanda ke nufin maganin adjuvant bayan tiyata don cutar kansar huhu ta EGFR mai kama da maye gurbi.

A ranar 9 ga Mayu, 2025, Hansoh Pharmaceutical ta sanar da cewa an amince da wata sabuwar alama ta Ameile (almonertinib mesylate allunan) don tallatawa. Sabuwar alamar tana nufin maganin da ke taimakawa ga manya marasa lafiya da ke fama da cutar kansar huhu ta ƙwayoyin halitta (NSCLC) waɗanda ciwonsu ke da maye gurbi na epidermal growth factor receptor (EGFR) exon 19 ko kuma maye gurbi na exon 21 (L858R), kuma waɗanda aka yi wa tiyatar cire ƙari. Ameile yanzu yana da alamomi guda huɗu da aka amince da su a China, yana riƙe da matsayinsa na gaba a tsakanin EGFR-TKIs na ƙarni na uku da suka ci gaba a cikin gida.

Wannan amincewar ta dogara ne akan binciken ARTS (HS-10296-302), wani gwaji na asibiti na Mataki na III wanda ba a tantance ba, wanda aka yi shi da makafi biyu, wanda aka sarrafa shi, kuma mai cibiyoyi da yawa. An gabatar da sakamakon binciken a matsayin rahoto na baki a taron shekara-shekara na Ƙungiyar Binciken Ciwon daji ta Amurka (AACR) na 2025.

Bayanai daga binciken ARTS da aka gabatar a taron shekara-shekara na AACR na 2025 sun tabbatar da cewa ga marasa lafiya da aka cire gaba ɗaya daga matakin II–IIIB EGFR-mutant NSCLC, maganin Ameile - idan ya dace - na iya inganta rayuwa ba tare da cututtuka ba (DFS). Adadin DFS na shekaru 2 ya kai 90.2%, tare da HR na 0.17, kuma gabaɗayan bayanin lafiyar ana iya sarrafa shi. Abin lura shi ne, binciken ya ƙunshi marasa lafiya 'yan China ne kawai, wanda ya nuna mahimmancin inganci da kuma yanayin aminci na EGFR-TKI da aka haɓaka a cikin al'ummar China.

Game da Ameile

A matsayinsa na farko na asali na EGFR-TKI na ƙarni na uku na ƙasar Sin, Ameile (Allunan Aumolertinib Mesilate) yana da kyakkyawan narkewar liposolution da kwanciyar hankali, wanda ke ba shi damar shiga shingen jini da kwakwalwa da kyau tare da ƙarancin yawan halayen da ba su da kyau. A halin yanzu, an amince da Ameile don alamu guda huɗu: magani na biyu ga marasa lafiya da suka kamu da cutar NSCLC ta hanyar gida ko ta hanyar maye gurbin T790M, waɗanda suka ci gaba a kan ko bayan maganin EGFR-TKI; magani na farko ga manya da ke fama da cutar NSCLC ta hanyar gida ko ta hanyar maye gurbin EGFR exon 19 ko kuma maye gurbin exon 21 (L858R) ta hanyar maye gurbin positive; magani ga marasa lafiya da suka kamu da cutar kansar huhu ta hanyar gida, wadda ba za a iya cirewa ba (Mataki na III) wanda ba ƙaramin ƙwayar cuta ba ce ("NSCLC") waɗanda cutar ba ta ci gaba ba bayan maganin chemoradiotherapy na platinum wanda ciwon daji ke da epidermal growth factor receptor (“EGFR”) exon 19 gogewa ko maye gurbin exon 21 (L858R); maganin taimako ga manya marasa lafiya da ke fama da cutar kansar huhu ta ƙwayoyin halitta (NSCLC) waɗanda ciwonsu ke da maye gurbi na epidermal growth factor receptor (EGFR) exon 19 ko kuma maye gurbi na exon 21 (L858R), kuma waɗanda aka yi wa tiyatar cire ciwon.

A halin yanzu, har yanzu akwai gwaje-gwaje da yawa na asibiti na sabbin fasahohin yaƙi da cutar kansa a China waɗanda ke neman marasa lafiya. Tuntuɓi kan sabbin magunguna da fasahohi, zaku iya tuntuɓar Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing.

Lambar Waya: 4008803716

Email：myimmnet@163.com